Clinical trial design in hepatocellular carcinoma.

Philip Johnson, Lucinda Billingham

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Researchers interested in developing treatments for hepatocellular carcinoma (HCC) face three sets of problems; one set common to all clinical trialists at the beginning of the 21st century, one set related to phase I/II studies ('early drug development') and one set related to the design of phase III (randomised, controlled trials). This review is concerned with the challenges faced in designing high quality clinical trials in patients with HCC. Specific published trials are not discussed other than by way of illustration of the problems faced.
Original languageEnglish
Pages (from-to)119-27
Number of pages9
JournalBest Practice & Research: Clinical Gastroenterology
Volume19
Issue number1
DOIs
Publication statusPublished - 1 Feb 2005

Keywords

  • trial design
  • hepatocellular carcinoma

Fingerprint

Dive into the research topics of 'Clinical trial design in hepatocellular carcinoma.'. Together they form a unique fingerprint.

Cite this